Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Quote & Options Analysis | Frenzy Capital
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $3.35 – $17.94
- YTD
- -57.16%
- IV Rank (30D)
- 42.83
- Straddle Price
- $2.93
- P/C Vol Ratio
- 0.17
- Market Cap
- $0.1B
- Exchange
- XNAS
- Market Cap
- $0.1B
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -2.33% | 1 |
| Feb | -3.25% | 2 |
| Mar | -39.46% | 2 |
| Apr | +40.55% | 2 |
| May | +0.97% | 1 |
| Jun | +26.12% | 1 |
| Jul | -4.35% | 1 |
| Aug | -9.59% | 1 |
| Sep | +47.67% | 1 |
| Oct | -22.08% | 1 |
| Nov | -3.29% | 1 |
| Dec | +38.16% | 1 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 56.8 | Neutral |
| MACD | -0.393 | Bearish |
| SMA 50 | $7.03 | Below |
| SMA 200 | $10.92 | Below |
| Bollinger Bands | Overbought | |
| ADX | 35.2 | Trend |
| HV 30 | 103.8% |
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Published | Title | Publisher | Sentiment |
|---|---|---|---|
| 2026-04-09 | Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman | GlobeNewswire Inc. | |
| 2026-03-11 | Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm | GlobeNewswire Inc. | |
| 2026-03-05 | NOTICE TO DISREGARD -- Pomerantz LLP | GlobeNewswire Inc. | |
| 2026-03-03 | INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD | GlobeNewswire Inc. | |
| 2026-03-02 | Stock Market Today: S&P 500, Dow, Nasdaq Futures Slide Amid US And Israel 'Operation Epic Furry' Against Iran— HKD, AARD, MDB In Focus (UPDATED) | Benzinga | |
| 2026-02-13 | Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GlobeNewswire Inc. | |
| 2025-11-03 | Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | GlobeNewswire Inc. | |
| 2025-07-18 | Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) | GlobeNewswire Inc. |
- IV Rank (30D)
- 42.83
- IV Rank (7D)
- 42.83
- Avg IV
- 341.0%
- Straddle (30D)
- $2.93
- Straddle (7D)
- $2.93
- P/C Volume
- 0.17
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 2.08
- Correlation (SPY)
- 24.0%
- R²
- 0.06
- Ann. Volatility
- 114.1%
- SPY Volatility
- 13.1%
High volatility - stock moves more than market
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 1.1 |
| P/S Ratio | 97.1 |
| EV/EBITDA | -1.1 |
| ROE | -54.0% |